Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome

Roufosse, Florence; Butterfield, Joseph H.; Steinfeld, Jonathan; Bentley, Johanne; Maltzahn, Robyn von; Kwon, Namhee; Nelsen, Linda

doi:10.3389/fmed.2023.1035250

Cited by 5 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the latter, pegylated interferon alpha 2a is regarded an effective and well-tolerated option, opposing the Th2 polarization of the condition (168). Regarding biologics, mepolizumab, an anti-IL-5 mAb recently approved for HES without an identifiable secondary non hematologic cause, resulted in good control of most HES manifestations; however, reported skin outcomes are conflicting (169).…”

Section: Wells Syndrome (Level Of Evidence 3a-4)mentioning

confidence: 99%

Neutrophilic and eosinophilic dermatoses associated with hematological malignancy

Maronese,

Derlino,

Moltrasio

et al. 2024

Front. Med.

View full text Add to dashboard Cite

Cutaneous manifestations of hematologic malignancy represent both a clinical challenge for the treating physician and a pathophysiological model for advancing the knowledge on individual neoplasms. Indeed, a growing body of evidence supports the concept of recurrent molecular defects associating with specific clinical features, as best exemplified by VEXAS. Herein neutrophilic and eosinophilic dermatoses of potential interest for both hematologists and dermatologists will be reviewed, including subcorneal pustular dermatosis-type IgA pemphigus, neutrophilic eccrine hidradenitis, Sweet’s syndrome as well as myelodysplasia cutis and VEXAS, pyoderma gangrenosum, eosinophilic annular erythema, eosinophilic dermatosis of hematological malignancy, Wells syndrome and cutaneous involvement in hypereosinophilic syndromes. Possible management approaches are discussed for each, emphasizing scenarios that require treatment of the underlying condition to achieve remission at the skin level.

show abstract

Section: Wells Syndrome (Level Of Evidence 3a-4)mentioning

confidence: 99%

Neutrophilic and eosinophilic dermatoses associated with hematological malignancy

Maronese,

Derlino,

Moltrasio

et al. 2024

Front. Med.

View full text Add to dashboard Cite

show abstract

Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals

Lübke,

Metzgeroth,

Reiter

et al. 2024

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Purpose of Review In this review, we aim to explore the optimal approach to patients presenting with eosinophilia, considering recent advances in diagnostic and therapeutic strategies. Specifically, we focus on the integration of novel therapies into clinical practice to improve patient outcomes. Recent Findings Advanced insights into the clinical and genetic features of eosinophilic disorders have prompted revisions in diagnostic criteria by the World Health Organization classification (WHO-HAEM5) and the International Consensus Classification (ICC). These changes reflect a growing understanding of disease pathogenesis and the development of targeted treatment options. The therapeutic landscape now encompasses a range of established and novel therapies. For reactive conditions, drugs targeting the eosinophilopoiesis, such as those aimed at interleukin-5 or its receptor, have demonstrated significant potential in decreasing blood eosinophil levels and minimizing disease flare-ups and relapse. These therapies have the potential to mitigate the side effects commonly associated with prolonged use of oral corticosteroids or immunosuppressants. Myeloid and lymphoid neoplasms with eosinophilia and tyrosine kinase (TK) gene fusions are managed by various TK inhibitors with variable efficacy. Summary Diagnosis and treatment rely on a multidisciplinary approach. By incorporating novel treatment options into clinical practice, physicians across different disciplines involved in the management of eosinophilic disorders can offer more personalized and effective care to patients. However, challenges remain in accurately diagnosing and risk-stratifying patients, as well as in navigating the complexities of treatment selection.

show abstract

Biologics in Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis

Ezekwe,

Weskamp,

Pittman

et al. 2024

Immunology and Allergy Clinics of North America

View full text Add to dashboard Cite

Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome

Cited by 5 publications

References 15 publications

Neutrophilic and eosinophilic dermatoses associated with hematological malignancy

Neutrophilic and eosinophilic dermatoses associated with hematological malignancy

Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals

Biologics in Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis

Contact Info

Product

Resources

About